Lex­i­con Phar­ma­ceu­ti­cals an­nounces mid-stage pain fail, blames dos­ing choice

A small Texas biotech is mov­ing a pain can­di­date for­ward in­to late-stage clin­i­cal de­vel­op­ment, de­spite a Phase II fail.

Lex­i­con Phar­ma­ceu­ti­cals told in­vestors Wednes­day that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER